Physician profile
Jay M Philippose
NPI 1992709364
$6,402.27
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $882 · 2020: $830 · 2021: $1,463 · 2022: $1,136 · 2023: $859 · 2024: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,909.71 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $1,095.40 | 2019-2024 | |
| Gilead Sciences, INC. | $832.65 | 2019-2024 | |
| Janssen Biotech, INC. | $555.75 | 2019-2024 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $219.01 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $191.62 | 2020-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $186.19 | 2024 | Iqirvo, Bylvay |
| Celgene Corporation | $183.18 | 2021-2024 | Zeposia |
| Evoke Pharma, INC. | $179.79 | 2023-2024 | Gimoti |
| Ardelyx, INC. | $166.18 | 2022-2023 | Ibsrela |
| Redhill Biopharma INC. | $124.64 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $91.95 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $80.58 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $74.73 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $67.71 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $66.40 | 2020-2022 | |
| Medtronic, INC. | $51.36 | 2021-2022 | |
| Boston Scientific Corporation | $44.67 | 2020-2023 | |
| Pfizer INC. | $44.22 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $37.92 | 2024 | |
| Allergan, INC. | $25.21 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $24.83 | 2022 | |
| Astellas Pharma US INC | $24.82 | 2024 | Veozah |
| Eisai INC. | $22.33 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.12 | 2022 | |
| Qol Medical, LLC | $18.79 | 2024 | Sucraid |
| Intra-Sana Laboratories | $18.33 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Capsovision, INC. | $15.20 | 2023 | Capsocam Plus |
| Vivus LLC | $14.85 | 2021 | |
| Shionogi INC | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Philippose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.